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Using Zinc Finger Nucleases and Homologous Recombination to Treat HIV/AIDS 
 
Section 1: Idea 
Introduction: 
  HIV/AIDS is a sexually transmitted infection that is transmitted by coming into contact 
with infected bodily fluids. According to the World Health Organization (WHO), it is the 
number 6 cause of death in the world, killing about 1.5 million people each year, and the current 
lifetime cost of treating HIV is about $379,000. In industrialized countries this maybe a possible 
option, but in third world countries, where the disease is most prevalent, if the treatment is even 
available, most people are not able to afford it. Some people are born with immunity to 
HIV/AIDS due to a genetic mutation, which causes misshapen proteins to form on the surface of 
their white blood cells. The deformed proteins prevent the HIV/AIDS virus from binding to the 
cells and ultimately infecting them. Using gene therapy, we can manually insert this mutation 
into cells and prevent them from getting infected by the HIV/AIDs virus. 
 
Background:  
The HIV/AIDS virus primarily binds to and replicates in CD4 T-cells, a type of white 
blood cell that is key in fighting off infections. Once it enters the cell the virus begins to 
replicate, and once the replication process is complete, the virus particles lyse the host cell and 
spread to replicate in other cells. The constant lysing of cells leads to a drastic drop in the 
number of CD4 T-cells in the body. In healthy uninfected individuals, a normal CD4 count, 
which measures the number of healthy and functioning CD4 T-cells in the blood, ranges from 
500 cells per cubic millimeter to 1,200 cells per cubic millimeter. Once a person’s CD4 count 
drops below 200 cells per cubic millimeter, they are considered to have AIDS, the final stage of 
the HIV infection (5). As the immune cells are being destroyed the body looses its ability to fight 
off infection, and the patient usually dies from an opportunistic illness.   
In order to enter the cell and 
begin replication, the virus must first 
bind to receptor proteins on the 
surface of the T-cell. The main 
binding protein for the virus is 
known as the CCR5 protein, which is 
coded for by the CCR5 gene. In 
some people, there is a mutation in 
the CCR5 gene resulting in a new 
gene called CCR5-delta 32. The 
mutation is the result of a 32-base 
pair deletion in the CCR5 allele (10), 
and the mutated version of the gene 
codes for a misshapen version of the 
CCR5 protein that the virus cannot 
bind to. Figure 1 shows, how the 
lack of the correct protein expression 
prevents most forms of the virus 
from binding to T-cells, essentially 
making these individuals immune to 
Figure	  1.	  In	  individuals	  who	  have	  one	  copy	  of	  the	  allele	  that	  codes	  
for	   the	   delta	   32	   mutation,	   the	   CCR5	   receptor	   is	   only	   slightly	  
misshapen,	  and	  the	  HIV/AIDS	  virus	  is	  still	  able	  to	  bind	  to	  it,	  but	  the	  
progression	  of	   the	  disease	   is	   slow.	  When	  both	   copies	  of	   the	  allele	  
code	   for	   the	   delta	   32	   mutation,	   the	   CCR5	   protein	   is	   completely	  
dysfunctional,	  and	  virus	  cannot	  bind	  to	  it	  (9). 
HIV/AIDS virus. If we are able to genetically modify the CCR5 gene to inhibit the correct 
production of the CCR5 surface protein, then we are able to prevent the virus from replicating in 
the body. Decreasing the replication of the virus in people who are already infected with HIV 
will greatly decrease the viral load and possibly cure those who are infected.  
Zinc Finger Nucleases (ZFNs) are small proteins that act as artificial restriction enzymes. 
To create ZFN’s Zinc Finger Proteins are combined with Fok-1 restriction enzymes (11).  Zinc 
Finger Proteins (ZFPs) are the 
binding domains of the complex. 
Each ZFP can recognize three to 
four base pairs in a DNA 
sequence, and it binds to the DNA 
by inserting its alpha-helix 
structure into the grooves of the 
double helix of the DNA (4). 
ZFPs can be created to target 
different domains on the DNA, 
and multiple ZFPs can be paired 
together to generate a recognition 
site of nine to eighteen base pairs 
(4).  Fok-I endonucleases are able 
to recognize specific DNA 
sequences and cleave the DNA at 
the target region (4). Figure 2., 
shows how these complexes are 
paired together so the ZFP 
functions as the binding domain, 
which identifies and binds to the target sequences in the DNA, and the Fok-1 endonucleases 
make the cuts in the DNA. The combination of these two complexes creates a novel protein, 
which is highly specific and has very accurate genome-editing capabilities. With this technology 
we can target the specific DNA sequence, which codes for the CCR5 surface protein. We can 
then cleave or cut the DNA at this specific region, and insert the CCR5 delta 32-gene to produce 
the misshapen surface protein. As the number of CCR5 negative CD4 T-cells in the body 
increases, the number of replicating viruses will decrease. This decrease in replication will help 
the immune system fight off the infection and ideally destroy the all of the virus particles within 
the body.  
After ZFNs cause the double stranded break in the DNA, the gene is edited by using 
either homologous recombination (HR) or non-homologous end joining (NHEJ). In HR, a 
corrected donor gene is inserted into the genome to replace the gene that was cut out (4). When 
using NHEJ, the DNA is left to repair and rejoin itself. This process can result in the random 
insertion and or deletion of nucleotides at the target site, which in turn, can result in defunct or 
“knocked out” genes (12). Figure 3. shows that in HR a donor gene is inserted into the genome, 
rejoining the ends in the target sequence that were cut by the ZFNs. In NHEJ, no gene is used to 
rejoin the ends, so the random insertion and or deletion of nucleotides results in a knocked out 
gene. Both of these processes can be applied to mutating the CCR5 gene. By using HR we can 
insert a constructed gene that contains the same sequence as the CCR5-delta 32 gene. The 
insertion of this donor gene would result in a modified version of the CCR5 surface protein, one 
Figure	   2.	   	   A.	   	   ZFN	   bind	   to	   DNA	   by	   using	   its	   alpha-­‐helix	   structure	   to	  
wedge	  itself	  into	  the	  grooves	  of	  the	  double-­‐helix	  structure	  of	  DNA.	  B.	  
Zinc	  Finger	  proteins	  act	  as	  the	  binding	  domains	  in	  ZFN;	  they	  identify	  
the	  target	  nucleotide	  sequence	  in	  the	  DNA.	  Fok-­‐1	  restriction	  enzymes	  
cleave	   the	  DNA	   at	   the	   targeted	   sequence.	   There	   are	   essentially	   two	  
parts	  to	  the	  ZFN	  a	  left	  half	  and	  right	  half,	  which	  are	  both	  imperative	  to	  
form	  the	  double	  stranded	  breaks	  in	  the	  DNA	  (11). 
that the HIV/AIDS virus could not 
bind to. We can also prevent the 
production of the protein through 
NHEJ. If the CCR5 gene is cut out 
of the genome, then the CCR5 
protein cannot be coded for; and in 
turn, it would not appear on the 
surface of the T-cells. 
Theoretically either method of 
causing the CCR5 mutation should 
prevent the virus from infecting the 
T-cells; however, the CCR5 
protein is the main receptor that the 
virus binds to, but it is not the only 
receptor. The virus also binds to a 
CD4 co-receptor and by knocking 
out the gene completely the virus 
may still be able to enter the cells 
(11).  
 
Significance and Innovation:  
High Active Antiviral Therapy (HAART) is the current treatment for HIV/AIDS. It 
includes a series of pills, which slow the replication process of the HIV/AIDS virus; however, 
HAART cannot rid the body of the virus so it is a lifetime treatment. The lifetime treatment of 
the disease greatly correlates with its highly expensive cost, which can reach up to $379,000. The 
treatment process entails a drug cocktail of multiple pills that must be taken daily. Which 
cocktail a patient receives is determined by many factors such as, the viral strain, the CD4 count, 
any other medical issues the 
patient may have. Figure 4 
shows how by not receiving or 
discontinuing the antiviral 
therapy, the virus can quickly 
replicate, opening the door to a 
whirlwind of issues and 
infections. The increase in viral 
load leads to the lysing of 
copious T-cells, and as a result 
the immune system is greatly 
weakened. This weakened 
immune system makes the 
patient susceptible to many 
ailments, which are even harder 
for the body to fight off 
because of the already 
weakened immune system. 
When taking multiple pills a 
Figure	  3.	  After	  ZFN	  makes	  double	  stranded	  breaks	   in	  the	  DNA,	   the	  
DNA	   is	   pieced	   back	   together	   in	   one	   of	   two	   ways.	   	   In	   non-­‐
homologous	   end	   joining,	   there	   is	   a	   random	   insertion	   and	   or	  
deletion	   of	   nucleotides,	   which	   leads	   to	   a	   gene	   being	   completely	  
dysfunctional	  or	  knocked	  out.	   In	  homologous	  end	   joining	  a	  donor	  
gene	   is	   inserted	   into	   the	  DNA,	  where	   the	   target	   sequence	  was	   cut	  
out.	   The	   new	   gene	   functions	   to	   either	   replace,	   act	   as	   a	   tag,	   or	   to	  
correct	  the	  gene	  that	  was	  targeted.	  	  (4)	  
Figure	   4.	   	   After	   stopping	   HAART,	   patients	   were	   subjected	   to	   gene	  
therapy	   HIV	   treatment.	   Once	   the	   HAART	   treatment	   stopped	   the	   viral	  
load	   increased	   drastically.	   Once	   the	   gene	   therapy	   was	   given	   the	   viral	  
load	  quickly	  declined	  to	  its	  original	  value.	  (12)	   
day it is not hard for a patient to forget a pill or even multiple pills a week, an event that can 
greatly impair his or her health. By using gene editing, we can create and infuse patients with 
CD4 T-cells that do not contain the CCR5 receptor. By infusing patients with the modified 
CCR5 negative T-cells, we are decreasing the number of available cells for the virus to bind to 
and replicate in. If the virus cannot replicate than the number of virus particles in the patients 
body should drastically decrease. Because the modification is permanent in those selected cells, 
this process should require little to no daily monitoring. As the number of viral particles 
continues to drop the immune system should strengthen and be able to help fight off the viral 
infection. Eventually, with the help of gene therapy the body should be able to eradicate the 
virus. Hopefully as the use of this technology increases and improves, it will become cheaper 
and widely available to multiple people in a variety of social classes.  
 
Section 2: Experimental System 
Objective. To determine if the infusion of CD4 T-cells that are negative for the CCR5 
protein, will decrease the viral load of individuals who are infected with the HIV/AIDS virus.  
Inserting the Mutation. To produce cells that are negative for the CCR5 receptor, 
autologous CD4 T-cells will be subjected to electroporation because the process is quick, easy, 
and it can be applied to multiple cells. During this process, cells will be suspended in a 
conductive solution, and a small electrical pulse will be generated. The pulse will disturb the 
phospholipid bilayer of the autologous CD4+ T-cells, which in turn will create small, temporary 
pores in the cell membrane. The small pores will allow the ZFNs to enter the cell. Once they 
enter the cell, ZFNs will produce double stranded breaks in the DNA at the region that codes for 
the CCR5 receptor. Through homologous recombination, a constructed CCR5-delta 32 gene will 
be inserted into the genome. This new gene, will code for the dysfunctional, misshapen version 
of the CCR5 surface protein.  
The experiment will be performed ex-vivo on a humanized-mouse model. All of the mice 
models will be infected with the virus and randomly assigned into groups. Each of the groups 
will be watched until it reaches a predetermined stage in the disease. In other words, the mice 
will be infected with the virus and observed until their CD4 count reaches a predetermined level. 
Once the desired level is reached, the group of mice will be infused with the autologous CD4 T-
cells that are negative for the CCR5 surface protein. This testing method will show how the 
treatment affects the viral load at different stages of the disease. In each group, there will be a 
small percentage of mice that act as a control and do not receive any treatment.  All of the mice 
will be tested every few days to monitor the changes in the viral load and the T-cell count.  
 
Future Goals: 
If this treatment method works it can be applied to a multitude of viruses that cause 
chronic infections that lead to disease. For example, the Hepatitis C virus is the blood borne 
version of the hepatitis virus that causes chronic hepatitis infection. This chronic infection can 
lead to liver diseases, which currently kills about 500,000 people each year (8). Through similar 
gene editing techniques used in the creation of the CCR5 negative CD4 T-cells, we can construct 
cells that are protected from infection by the Hepatitis virus. After identifying which cells the 
virus targets and which surface proteins the virus needs to enter those cells, we can use the ZFN 
nucleases to cut and remove the gene that codes for those proteins. If genes that make people 
immune to hepatitis C exist, then through homologous recombination, they can be inserted as a 
replacement gene in the genome. If no such gene exist or cannot be created through current lab 
techniques, then non-homologous end joining can be used to knockout the gene that codes for the 
protein. Either method would result in a dysfunctional gene, and in turn, would either produce 
cells that have a mutated protein or cells that do not display the protein. This will prevent the 
virus from binding to the cells; and therefore, prevent the infected individual from developing 
liver disease. These methods can be used to prevent the development of copious diseases that are 
caused by chronic viral infections.  
Gene editing can also be used to treat different forms of cancer. Research has shown that 
some viruses can lead to the development of some cancers such as Hodgkin’s Lymphoma, 
Cervical Cancer, and Liver Cancer. These viruses, known as oncoviruses, target healthy cells and 
mutate them by inserting mutations into their genome, and these mutations lead to the 
development of cancer. Like all viruses, oncoviruses can only replicate inside cells, and each 
virus must bind to a specific receptor on a specific cell. For the oncoviruses that cause chronic 
infection, using ZFNs and other gene editing techniques, the receptors for the viruses can be 
removed from the cells. If the virus cannot infect the cells, then the cells will not receive the 
mutation that the virus induces during its replication process, and the cells will not become 
cancerous.  
Another possible implication of this gene editing techniques, though it has some moral 
and ethical backlash, is the creation of embryos that are immune to common life threatening 
diseases. The HIV/AIDS virus currently infects about 35 million people worldwide, and about 
3.2 million of those individuals infected are under the age of 15 (7). By using the previous 
techniques to insert the CCR5-delta 32 gene into germ cells, we can create children who are born 
completely immune to most forms of the HIV/AIDS virus.  As gene editing becomes more 
prevalent and costs for it decreases, this could be extremely beneficial. Individuals, who receive 
the mutation before birth, would pass that genetic mutation to their offspring, who can then pass 
the mutation to their offspring. Overtime, this prevention method becomes cheaper than the 
current treatment for disease. Instead of paying  $379,000 in a lifetime to treat a disease, 
individuals would be able to pay a single price to prevent the disease for generations. For areas 
that have high HIV/AIDS rate, this process has the opportunity to save many lives. As the 
number of people who are born immune to the virus increases, the incident rate of the disease 
should greatly decrease. Theoretically, if this happens then the diseases should eventually be able 
to be eradicated from the population.  Even though there is currently a lot of controversy, about 
“designer babies” and using gene editing to create children with specific desired traits, using 
gene editing to give people immunity to lethal infections and diseases that deprecate the quality 
of life should be considered.  
 All in all, the use of ZFN and gene editing technology can be used to treat and 
prevent a variety of diseases that are caused by chronic viral infections. By targeting genes that 
code for different surface proteins we are able changing the expression of the proteins, and 
prevent viruses from being able to bind to and replicate in the cells. If the virus cannot replicate, 
then they cannot cause disease. These processes can be applied to somatic cells and germ cells, 
allowing people to be immune to specific viral infections before birth. If it is successful and 
somewhat widely accepted by the general public, this process has the opportunity to save 
millions of lives worldwide.  
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